Scott Halperin

Last updated

Scott Halperin is a Canadian immunologist, professor of pediatrics, microbiology, and immunology at Dalhousie University, the head of Pediatric Infection Diseases at IWK Health Centre, and the director of the Canadian Center for Vaccinology. [1] [2] [3]

Contents

Biography

Halperin received a B.Sc. from Stanford University, and an M.D. from Cornell University. He did his postdoctoral research in pediatric infectious diseases at the University of Virginia and University of Minnesota. [4]

Career

Halperin's research focuses on pertussis and other vaccine-preventable diseases. [2] In 2020, the Canadian Centre for Vaccinology at Dalhousie University was approved by Health Canada to begin clinical trial for a potential COVID-19 vaccine, led by Halperin. [5] Halperin's research also focuses on public health policy in relation to the COVID-19 pandemic. [6]

Awards

From 2004 to 2009, Halperin held the CIHR/Wyeth Pharmaceuticals clinical research chair in vaccines. He received a certificate of merit from the Canadian Paediatric Society in 2009, as well as the Max Forman Senior Research Prize from the Dalhousie Medical Research Foundation, also in 2009. [4]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Peter Hotez</span> American scientist, pediatrician, and advocate

Peter Jay Hotez is an American scientist, pediatrician, and advocate in the fields of global health, vaccinology, and neglected tropical disease control. He serves as founding dean of the National School of Tropical Medicine, Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine, where he is also Director of the Texas Children's Hospital Center for Vaccine Development and Endowed Chair in Tropical Pediatrics. He also serves as a University Professor of Biology at Baylor University.

<span class="mw-page-title-main">Oxford Vaccine Group</span> Research group of the University of Oxford

The Oxford Vaccine Group (OVG) is a vaccine research group within the Department of Paediatrics at the University of Oxford. It was founded in 1994 by Professor E. Richard Moxon, was initially based at the John Radcliffe Hospital, and moved in 2003 to its current location in the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) at the Churchill Hospital in Oxford, England. The group, led by Professor Andrew Pollard since 2001, comprises around 75 members across a number of disciplines, including consultants in paediatrics and vaccinology, clinical research fellows, research nurses, statisticians, post-doctoral laboratory scientists, research assistants and DPhil students.

Gagandeep Kang FRS is an Indian microbiologist and virologist who has been leading the work on enteric diseases, diarrheal infections and disease surveillance at the Bill & Melinda Gates Foundation since 2023.

<span class="mw-page-title-main">Moderna COVID-19 vaccine</span> RNA COVID-19 vaccine

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus.

<span class="mw-page-title-main">Bonnie Henry</span> Canadian public health officer

Bonnie J. Fraser Henry is a Canadian epidemiologist, physician, and public servant who has been the provincial health officer at the British Columbia Ministry of Health since 2014. Henry is also a clinical associate professor at the University of British Columbia. She is a specialist in public health and preventive medicine, and is a family doctor. In her role as provincial health officer, Henry notably led the response to COVID-19 in British Columbia (BC).

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

<span class="mw-page-title-main">Kizzmekia Corbett</span> American immunologist

Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is an Assistant Professor of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and the Shutzer Assistant Professor at the Harvard Radcliffe Institute since June 2021.

<span class="mw-page-title-main">Arnold Monto</span> American physician and epidemiologist

Arnold Monto is an American physician and epidemiologist. At the University of Michigan School of Public Health, Monto is the Thomas Francis, Jr. Collegiate Professor Emeritus of Public Health, professor emeritus of both epidemiology and global public health, and co-director of the Michigan Center for Respiratory Virus Research & Response. His research focuses on the occurrence, prevention, and treatment of viral respiratory infections in industrialized and developing countries' populations.

<span class="mw-page-title-main">Solidarity trial</span> Accelerated multinational clinical trial program to identify therapies against COVID-19

The Solidarity trial for treatments is a multinational Phase III-IV clinical trial organized by the World Health Organization (WHO) and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. The trial was announced 18 March 2020, and as of 6 August 2021, 12,000 patients in 30 countries had been recruited to participate in the trial.

<span class="mw-page-title-main">Convidecia</span> Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

<span class="mw-page-title-main">Scott Halstead</span> American scientist and virologist

Scott Halstead is an American physician-scientist, virologist and epidemiologist known for his work in the fields of tropical medicine and vaccine development. He is considered one of the world's foremost authorities on viruses transmitted by mosquitoes, including Dengue, Japanese encephalitis, chikungunya and Zika. He was one of the first researchers to identify the phenomenon known as antibody-dependent enhancement (ADE), where the antibodies generated from a first dengue infection can sometimes worsen the symptoms from a second infection.

<span class="mw-page-title-main">Covaxin</span> Vaccine against COVID-19

Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

<span class="mw-page-title-main">Novavax COVID-19 vaccine</span> Vaccine against COVID-19

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations. It contains a recombinant spike protein from the SARS-CoV-2 Omicron variant lineage JN.1.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi, is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwatersrand.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

Dr. Shelley Deeks, MD, MHSc, FRCPC, FFAFPM, is a Canadian public health expert who is the chair of the National Advisory Committee on Immunization. Her advertised "specialities include communicable disease control, outbreak investigations, vaccine safety, epidemiology and program evaluation." She is a fellow of the Royal College of Physicians of Canada and the Australian Faculty of Public Health Medicine. Deeks was the executive lead in Ontario's COVID-19 pandemic response in 2020 in her role at Public Health Ontario.

Peter Jüni is a Swiss physician, general internist, and epidemiologist based in England.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

Helen Siobhan Marshall is an Australian medical researcher who is Professor of Vaccinology at the University of Adelaide. She was named the South Australian of the Year for 2022.

References

  1. "COVID‑19 researcher profile: Dr. Scott Halperin". Dalhousie News. Retrieved 17 May 2020.
  2. 1 2 "» Dr. Scott Halperin". 8 April 2013. Retrieved 17 May 2020.
  3. "Health Canada approves first clinical trial for potential COVID-19 vaccine". rdnewsnow.com. The Canadian Press. Retrieved 17 May 2020.
  4. 1 2 "Scott Halperin". Dalhousie University. Retrieved 17 May 2020.
  5. Keith Doucette (17 May 2020). "Halifax lab to do COVID-19 vaccine trials". Winnipeg Free Press. The Canadian Press. Retrieved 17 May 2020.
  6. Cooke, Alex (9 March 2020). "Dalhousie researchers get $1.9M to study coronavirus". CBC. Retrieved 17 May 2020.